Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 21st October 2020 from 07:00 AM to 07:00 PM (BST).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 83, 2020
Previous Article Next Article

Two-photon photodynamic ablation of tumour cells using an RGD peptide-conjugated ruthenium(ii) photosensitiser

Author affiliations

Abstract

An RGD-peptide conjugated ruthenium(II) complex has been developed, which functions as a two-photon absorption (TPA) photodynamic therapy (PDT) agent for ablating tumours by selectively targeting the mitochondria of integrin αvβ3-rich tumour cells. This approach offers a new and effective design and application for tumour-targeting metallo-anticancer drugs via two-photon PDT.

Graphical abstract: Two-photon photodynamic ablation of tumour cells using an RGD peptide-conjugated ruthenium(ii) photosensitiser

Back to tab navigation

Supplementary files

Article information


Submitted
19 Jul 2020
Accepted
08 Sep 2020
First published
09 Sep 2020

Chem. Commun., 2020,56, 12542-12545
Article type
Communication

Two-photon photodynamic ablation of tumour cells using an RGD peptide-conjugated ruthenium(II) photosensitiser

Z. Zhao, K. Qiu, J. Liu, X. Hao and J. Wang, Chem. Commun., 2020, 56, 12542
DOI: 10.1039/D0CC04943C

Social activity

Search articles by author

Spotlight

Advertisements